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Abstract
Accurate and quantitative dosimetry for internal radiation therapy can be especially challenging, given the
heterogeneity of patient anatomy, tumor anatomy, and source deposition. Internal radiotherapy sources such as
nanoparticles and monoclonal antibodies require high resolution imaging to accurately model the heterogeneous
distribution of these sources in the tumor. The resolution of nuclear imaging modalities is not high enough to
measure the heterogeneity of intratumoral nanoparticle deposition or intratumoral regions, and mathematical
models do not represent the actual heterogeneous dose or dose response. To help answer questions at the
interface of tumor dosimetry and tumor biology, we have modeled the actual 3-dimensional dose distribution of
heterogeneously delivered radioactive nanoparticles in a tumor after systemic injection.
Methods: 24 h after systemic injection of dually fluorescent and radioactive nanoparticles into a tumor-bearing
mouse, the tumor was cut into 342 adjacent sections and imaged to quantify the source distribution in each
section. The images were stacked to generate a 3D model of source distribution, and a novel MATLAB code was
employed to calculate the dose to cells on a middle section in the tumor using a low step size dose kernel.
Results: The average dose calculated by this novel 3D model compared closely with standard ways of calculating
average dose, and showed a positive correlation with experimentally determined cytotoxicity in vivo. The high
resolution images allowed us to determine that the dose required to initiate radiation-induced H2AX
phosphorylation was approximately one Gray. The nanoparticle distribution was further used to model the dose
distribution of two other radionuclides.
Conclusions: The ability of this model to quantify the absorbed dose and dose response in different intratumoral
regions allows one to investigate how source deposition in different tumor areas can affect dose and cytotoxicity,
as well as how characteristics of the tumor microenvironment, such as hypoxia or high stromal areas, may affect
the potency of a given dose.
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Background
Quantitative radiation dosimetry requires knowledge of
both patient anatomy and distribution of the absorbed
dose. Improvements in dosimetric models have been seen
not only in external beam radiation therapy, but also in
dose planning for several types of internal radiation ther-
apy, including in brachytherapy [1, 2], selective internal
radiation therapy [3, 4], and radioimmunotherapy [5–7].
Accurate dosimetry for internal radiation therapy can be
especially challenging, given the heterogeneity of patient
anatomy, tumor anatomy, and source deposition. As radio-
therapy sources have become smaller and their deposition
less controlled—from brachytherapy seeds to 90Yttrium
(90Y) microspheres to radionuclide-chelated monoclonal
antibodies administered systemically—more accuracy is
needed to determine the increasingly heterogeneous
distribution of the sources, and how this distribution affects
therapeutic outcomes. Because of this, a huge amount of
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effort has been invested in the creation of dosimetric
algorithms to analyze dose deposition and dose–response in
clinical and preclinical models. Some of these models are
based on theoretical calculations that make educated as-
sumptions about source deposition [8–11], while others use
nuclear imaging methods such as single photon emission
computed tomography (SPECT) to approximate the source
distribution [4, 5, 12]. Although theoretical models can help
one quickly change parameters and estimate outcomes, the
calculated distributions do not represent the actual
heterogeneity of source and dose distribution in a tumor.
While some preclinical SPECT scanners have been accepted
as quantitative [13] and achieved sub-millimeter spatial
resolution [14, 15], the gamma camera on clinical scanners
is only ~10 mm [16]. Positron emission tomography (PET)
is known to have greater sensitivity than SPECT, but its
resolution is bound to the energy of the positron itself as
well as to the detector limits [17]. Positrons with higher en-
ergy at the time of ejection travel a longer distance from the
source before their detectible annihilation reaction, resulting
in an additional contribution to spatial resolution of over 0.5
mm for [18] Fluorine and greater than 6 mm for 82Rubid-
ium [17]. In either modality, the reconstructed images are
not near cellular resolution, and may have trouble distin-
guishing source deposition within different tumor areas.
We have generated a high resolution dose map with a
voxel size of 10 μm3 from an actual 3-dimensional (3D)
intratumoral distribution of systemically delivered radio-
active nanoparticles, and have used this dose map to
quantify the dose in Gray (Gy) to each cell in a section of
the tumor. We have also successfully correlated increasing
dose with increasing DNA double-stranded break repair
via phosphorylation of H2AX, an enzyme that is phos-
phorylated in response to DNA double-stranded breaks,
and is the most representative marker of DNA damage
caused by ionizing radiation [18]. The following represents
a proof-of-concept that this type of high-resolution correl-
ation is possible and may provide ways to strengthen our
understanding at the interface of biology and dosimetry.
Methods
Materials
177Lutetium Chloride (177LuCl3) was purchased from
PerkinElmer (Waltham, MA). N-(Carbonyl-methoxypo-
lyethyleneglycol 2000)-1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine, sodium salt (DSPE-PEG2000) was
purchased from NOF America Corporation (White Plains,
NY). DSPE-PEG2000-Anisamide (DSPE-PEG-AA) was
synthesized in our lab as described previously [19]. 1,2-
dioleoyl-sn-glycero-3-phosphate (DOPA) and 1,2-dioleoyl-
3-trimethylammonium-propane (DOTAP) were pur-
chased from Avanti Polar Lipids (Alabaster, AL). Primary
antibody against p-H2AX was purchased from Cell Signal-
ing (Rabbit mAb #9718). Anti-rabbit secondary antibody
was purchased from Cellsignaling (#4414). Other chemi-
cals were purchased from Sigma-Aldrich (St. Louis, MO)
or ThermoFisher (Waltham, MA).
Cell lines
UMUC3 human bladder cancer cells and NIH/3T3 (3T3)
murine fibroblasts were used in the described experi-
ments. UMUC3 cells were grown in Dubelcco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin. 3T3 cells
were grown in DMEM supplemented with 10% bovine calf
serum and 1% penicillin/streptomycin.
Experimental animals
Female athymic nude mice aged six to eight weeks were
used for all experiments. The mice were purchased from
the National Cancer Institute (Bethesda, MD) and bred at
the Division of Laboratory Animal Medicine at the
University of North Carolina-Chapel Hill. All work per-
formed on these animals was approved by the Institutional
Animal Care and Use Committee at the University of
North Carolina-Chapel Hill, protocol #14-045.
DiI-177Lu-LCP fabrication
Fabrication of the 177Lu-loaded Lipid-Calcium-Phosphate
(LCP) nanoparticle (177Lu-LCP) is well characterized and
has been described previously [20–23]. In brief, 177Lu was
co-precipitated with calcium, phosphate, and the
phospholipid DOPA in a reverse microemulsion. The
resulting nanoparticle core was dissolved in chloroform
and the outer leaflet lipids DOTAP, cholesterol, and
DSPE-PEG-AA were added to the chloroform solution.
The lipophilic dye DiI was also added to the chloroform
before evaporating the solution into a lipid film on the
slides of a glass vial. Adding water to hydrate the lipid
film, followed by vortexing and sonication, allowed the
free lipids to arrange themselves around the nanoparticle
cores and form a lipid bilayer that was soluble in water.
The DiI accumulated in the lipophilic bilayer of the LCP
nanoparticles, and excess DiI was removed using sucrose
gradient centrifugation. DiI was chosen as a marker for
LCP because it has previously been shown to be a faithful
label of lipid bilayers [24].
177Lu-LCP pharmacokinetic study
177Lu-LCP was injected intravenously into n = 5 female
athymic nude mice in a 10% w/v sucrose/water solution. At
0.5, 1, 2, 4, 8, and 24 h after injection, ~20 μL of blood was
collected from each mouse and measured for 177Lu using
gamma scintillation. This value was used to estimate the
amount of 177Lu remaining in circulation, and therefore the
amount of 177Lu in the tumor, assuming that the tumor
accumulation was proportional to the fraction of the
injected dose that had left circulation at that time, with the
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maximum tumor accumulation occurring at t = 24h and a
total blood volume per mouse of 1.8 mL. 177Lu-LCP was
formulated with DOTAP in the outer leaflet in order to
decrease circulation time and expedite tumor accumulation
of the nanoparticles. Time dependent tumor accumula-
tion was used for all dosimetry models herein. The
rationale for this method is expanded in Additional file 1,
and data is presented in Additional file 2: Table S1 and
Additional file 3: Figure S1.
Standard dose calculations (MIRD and single point source)
We used two separate methods to help justify our mul-
ti-point source dosimetric approach. The Medical In-
ternal Radiation Dose (MIRD) formula was used to
calculate the dose to the tumor assuming homogeneous
source delivery. The full derivation of the MIRD dose is






tð Þdt was used to calculate the dose
of 177Lu to the tumor [3, 6, 7, 25, 26].
Dose kernels for point sources in an infinite water
medium [27–29] were also used to approximate the dose,
assuming that all activity was contained in a single point
source and that the absorbed fraction was one. The dose
at r = 0 was adjusted as described in the next section to
avoid an asymptotic rise in dose at the source. The dose
calculated from MIRD and by kernel values was compar-
able (Additional file 4: Table S2) and supports the use of
dose kernels for this new multi-point source model.
Decay of 177Lu and the kinetics of 177Lu-LCP accumu-
lation in the tumor were accounted for within these
calculations.
Novel dose kernel calculations (multi-point source)
In short, these novel dose calculations aim to determine
the dose to each cell in a tumor section by calculating
the activity present in each 10 μm3 voxel within a 3D
reconstructed tumor. Each voxel is treated as its own
point source with its own set of dose kernels. For our
dose kernel calculations, the density of tumor tissue was
assumed to be that of water, and would therefore not
perturb the kernel values or dose deposition. Concentra-
tion of LCP nanoparticles in the tumor was calculated to
be approximately ten parts per million (weight:weight);
it was assumed that these nanoparticles also did not per-
turb the kernel calculations. Dose kernels were interpo-
lated so that the length of each kernel was 10 μm
(Additional file 4: Table S3 and Additional file 5: Table S4).
This did not change the total absorbed dose with respect to
the un-interpolated kernels. It is known that dose kernels
can lose fidelity at small distances due to the inverse square
law (explained in the publication also providing the kernels
themselves [27]), so to avoid an unrealistic asymptotic rise
in dose deposition at distances close to r = 0, values at small
r were set so that those rates would decrease exponentially
with increasing r. In this way, the total absorbed dose of
both the interpolated and un-interpolated kernels were
comparable to the dose calculated by the MIRD formula, as
shown in Additional file 4: Table S2.
To estimate the dose absorbed by each cell nucleus
from a given point source, the average number of nuclei
in each annular kernel volume (annular volume = 4/
3πr2
3-4/3πr1
3, with r2-r1 = 10 μm) was calculated using an
actual fluorescent image of the nuclear distribution in
the tumor (Additional file 6: Figure S3). From this
image, the volume fraction occupied by all cell nuclei
was 0.4, and the average size of a cell nucleus was ~ 10
μm3. To calculate the statistical dose to each nucleus in
each annulus from a point source, the total dose depos-
ited in an annulus was divided by the number of nuclei
in that annulus and multiplied by the average volume
fraction occupied by nuclei in the tissue. The dose per
nucleus was calculated because our fluorescent images
did not clearly define cell boundaries and what fraction
of the tumor consisted of extracellular matrix, etc.
Microdosimetry
Intratumoral nanoparticle distribution was quantified by
first formulating DiI-177Lu-LCP (described above) and
systemically injecting these radioactive and fluorescent
particles into the tail vein of a UMUC3/3T3 tumor-
bearing mouse. At t = 24 h after treatment, the tumor
was dissected, fixed, and frozen in OCT. The frozen
tumor was then sectioned into 342 adjacent sections,
each 10 μm thick, which were mounted on slides and
stained with DAPI. Each section was individually imaged
for DAPI and DiI fluorescence at the Translational Path-
ology Lab at The University of North Carolina at Chapel
Hill (UNC) with the Aperio Versa 200 digital pathology
scanner (Leica Biosystems Richmond, Inc., USA), which
digitally scanned the entire tumor section on each slide
with a resolution of 0.32 μm/pixel. Each section was
examined for artifacts such as folding or breakage of the
section; slides with major artifacts were replaced with a
duplicate of their adjacent section (only 24 out of 342
slides were replaced). Slight creasing in some sections
also caused small areas of falsely positive DiI signal,
which were removed by setting the value of the bright
pixels along the crease to zero. For each 8-bit grayscale
image, background subtraction was set to remove all
noise at intensity ≤ 20 (out of 255).
Five slides—#003, 301, 302, 303, and 340—were imaged
before all others and were used to generate a correlation
between DiI signal and radioactivity in the tissue. Imaging
all 342 slides took a significant amount of time, but by
quickly imaging these select slides while the radioactivity
was still high enough to be measured using liquid
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scintillation counting, we could determine this correlation.
After these slides had been imaged for their DiI distribu-
tion, their coverslips were removed and the tissues were
wiped off using a small piece of Kimwipe. Any residual tis-
sue was collected by using two additional Kimwipes to
wipe the slide. Each tissue, now on a Kimwipe, was placed
in a 7 mL glass scintillation vial filled with 4 mL of Ultima
Gold scintillation cocktail. After vortexing and sonicating
each vial to saturate the tissue with scintillation fluid, the
vials were read for radioactivity using a liquid scintillation
counter and compared against a calibration curve of
known amounts of 177Lu radioactivity. The amount of
radiation per tissue sample, in Bq, was adjusted for six
days of decay between injection of nanoparticles and this
quantification. The total amount of DiI fluorescence in
each of these samples was also quantified as the total
number of relative fluorescence units (RFU) per section.
The Bq per RFU in each of the five sections was calculated
and averaged to be 5.3E-5 ± 1.5E-5 (Avg ± SD). This factor
was then used to calculate the total radioactivity in all 342
samples.
The DiI distribution files for each of the 342 sections
were converted to TIFF images and downsampled so that
each pixel was ~10 μm2. Now each pixel represented a 10
μm3 voxel due to the 10 μm thickness of each section. All
sections were then registered using the StackReg plugin in
the FIJI image processing software so that all images could
be converted to a 3D stack that represented the 3D tumor.
StackReg rotated and translated each section to co-
localize its outline and features with the adjacent section
in the stack. A middle section in the stack, section 171,
was the section on which the dose map was calculated.
A novel algorithm was created in MATLAB and
executed on the University of North Carolina’s Killdevil
computing cluster to create the dose distribution map
describing the cumulative deposited dose from all voxels
in all sections onto section 171. The algorithm measured
the (x,y,z) coordinates for all 10 μm3 voxels in the stack
and individually determined the straight line distance (r)
from each voxel to every voxel in section 171. The dose
contribution corresponding to each distance (r) was
calculated using our interpolated dose kernel values and
adjusted to reflect the concentration of DiI-177Lu-LCP in
the voxel (as described in the previous paragraph). In this
way, each voxel in the stack was treated as a distinct
source with an activity calculated from its fluorescence in-
tensity and a dose distribution based on the dose kernel.
p-H2AX quantification
To further validate our dosimetry method, and also to
quantify the dose required to initiate an increased rate of
DNA damage repair, section 171 was stained for the DNA
double-stranded break repair enzyme p-H2AX using
immunofluorescence. After imaging the DiI distribution
in section 171, the coverslip was removed and the section
was re-stained and re-imaged. The dose map was then
overlaid on the p-H2AX distribution map in order to cor-
relate absorbed dose with p-H2AX expression (Fig. 4).
Quantifying dose distributions for other nuclides
Dose kernels [27] for 33Phosphorus (33P) and 90Y were
used to calculate the dose distribution of these nuclides
from the same 3D nanoparticle (source) distribution
used for 177Lu. The dose kernels for 33P and 90Y were
interpolated and used to create a new overall dose map
onto section 171. In this way, we could compare
differences in dose distributions from a single source
distribution. Results are provided in Fig. 5.
Calculating radial dose distribution
In order to measure what fraction of the total dose to a
cell was contributed by radiation sources at different
distances away from that cell, a completely separate and
hypothetical source distribution was used. We generated
a 3D field of homogeneous radioactivity and used the
interpolated dose kernels for 177Lu, 90Y, and 33P to
calculate the dose contribution onto one 10 μm3 voxel
(a “cell”) from each 10 μm-thick spherical annulus
emanating outward. Results are provided in Fig. 6.
Results
To generate the tumor for our model, a nude athymic
mouse bearing a UMUC3/3T3 tumor [20, 30] was treated
with lipid-calcium-phosphate nanoparticles that were
loaded with 177Lu and labeled with fluorescent DiI (DiI-
177Lu-LCP). Twenty-four h after treatment, the tumor was
dissected and weighed. At this time, the 0.13 g tumor was
measured to contain 60.3 kBq of 177Lu using gamma
scintillation. The dose to the tumor at each time point
between t = 0 and t = 24 h was adjusted to reflect radio-
active decay, as well as tumor accumulation over time as
described in the Additional file 2: Table S1 and Additional
file 3: Figure S1 pharmacokinetic studies.
The tumor in question was fixed, frozen, sectioned
into 342 adjacent sections, and imaged to quantify DiI-
177Lu-LCP distribution (red color, Fig. 1a). The DiI
channels for each image (Fig. 1b) were registered and
stacked to create a 3D model (Fig. 1c) of the tumor’s DiI
distribution. A rendering of this 3D model is provided as
a video in Additional file 7: Figure S4.
In order to determine if DiI distribution could indeed be
used to model 177Lu distribution, five of the imaged tumor
sections were wiped from their slides and read using
liquid scintillation counting against a calibration curve of
free 177Lu. The total radioactivity in each of these imaged
sections was divided by each section’s total fluorescence to
arrive at an average value for Bq/RFU of 5.27E-05 (using
time t = 0 to account for decay). Applying this factor to all
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sections yielded a total of 52.9 kBq in all sections
combined at t = 24 h, which was ~88% of the total activity
in the intact tumor. The slight discrepancy in total radi-
ation is due at least in part to the front and back ends of
the tumor not being included in the 342 sections used to
create this model. Therefore, it was reasonable to use the
DiI distribution as a surrogate marker for the 3D distribu-
tion of 177Lu in the tumor.
At this point, the 177Lu concentration in every 10 μm3
voxel in the 3D DiI model was known, and each voxel was
considered its own point source. Using the interpolated
dose kernels shown in Additional file 4: Table S3, a dose
map was created onto a middle section in the stack: sec-
tion 171. A novel MATLAB code (described in Methods)
was used to calculate the distance—and therefore the dose
contribution—of each voxel in each section to each voxel
in section 171. Figure 2 shows how four different parame-
ters change as distance from the source, and therefore the
annular inner diameter, increases. Annular volume and
nuclei per annulus (A and B) both increase exponentially.
Absorbed dose per annulus increases slightly at short dis-
tances before dropping, while dose per nucleus shows a
sharp decrease at short distances followed by a continued
decrease (C and D).
The overall dose map generated from the multitude of
dose contributions onto section 171 (Fig. 3a) was overlaid
onto the cell nucleus distribution image (3B) and the dose
to each cell nucleus was calculated (3C). The maximum
dose per nucleus over the 24 h period was ~2.5 Gy, and
the average dose for all nuclei in the section was 0.84 Gy,
which is just slightly lower than the average dose calcu-
lated by MIRD (0.91 Gy) or by dose kernels for a single
point source (1 Gy). This slight discrepancy is due at least
in part because some of the dose is distributed outside the
tumor region, especially from nanoparticles along the
tumor edge. Heterogeneous nanoparticle distribution
could also lead to a mean absorbed dose in a section of
the tumor that differs from the absorbed dose throughout
the entire tumor. Nonetheless, this value, calculated from
the dose contributions of many small and heterogeneously
distributed point sources, is similar to the average dose
calculated from the standard methods described above,
suggesting that our novel method is indeed accurate.
To further validate this method of calculating heteroge-
neous microdosimetry, we removed the coverslip from the
middle section and re-stained the tissue for p-H2AX using
immunofluorescence. The re-stained section was imaged
for DAPI and p-H2AX (Fig. 4b) and overlaid on the dose
map (4A) in order to correlate p-H2AX distribution with
radiation dose. Figure 4c shows a histogram of the total
number of cells that received a certain dose of radiation
(bin size = 0.1 Gy), and Fig. 4d shows the total number of
p-H2AX positive cells that received a certain dose.
Figure 4e combines these two histograms to show that
cells which received a higher dose according to our model
also had a higher percentage of p-H2AX positive cells.
This important figure shows a positive correlation be-
tween our model of dose distribution generated from the
actual heterogeneous deposition of radiation sources, and
the experimentally determined effect of the incident
radiation on the cells (H2AX phosphorylation). The figure
indicates that radiation-induced H2AX phosphorylation
occurs in some cells at a dose as low as approximately one
Gy, with an increased dose inducing p-H2AX in an in-
creased percentage of cells.
While the nanoparticles used in this study were loaded
with 177Lu, we can imagine that other nuclides could
potentially be loaded into the nanoparticles instead. In this
example, the cellular response (e.g. p-H2AX) to the nano-
particle and dose distribution is only valid for 177Lu, but the
measured nanoparticle distribution can be used to compare
how the dose kernels of different nuclides may affect the dose
distribution and dose rate to the cells in section 171. The
beta emissions from the clinically used 90Y have more
energy and thus a longer path length in tissue; in this case,
areas with a higher nanoparticle density may be able to
Fig. 1 Intratumoral DiI-177Lu-LCP Distribution: a) two-channel image of DAPI nuclear stain (blue) and DiI (red) in section 171; b) Isolated and
background-subtracted DiI signal; c) 3D stack of 342 adjacent tumor sections
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deposit dose onto faraway cells that are located in areas of
low nanoparticle density. Of course, this may also lead to a
higher dose onto healthy tissue adjacent to the tumor, espe-
cially from 90Y deposited near the tumor edge. In contrast,
the beta emissions from the radionuclide 33P deposit nearly
all of their energy very close to the source, leading to very
high radiation doses only in areas of high nanoparticle
density. Figure 5a, b, and c show the dose maps and indi-
vidual scale bars (in Gy) for 177Lu, 33P, and 90Y, respectively,
and Fig. 5d, e, and f show the overlay of cell distribution for
these dose maps. By comparing the scale bars, one can see
that 90Y not only provides a more homogeneous dose
throughout the left side of tumor section, but also imparts
a much larger dose given the same amount of radioactivity
(in Bq). This is shown more clearly in Fig. 5g, h, and i,
which show the dose maps for 177Lu, 33P, and 90Y using the
same scale bar min and max.
We were also interested in changing our perspective to
the viewpoint of the cell. We asked what fraction of the
total dose to a cell was contributed by radiation sources at
different distances away from that cell. For example, at dis-
tances very close to a cell, there may be very few particles
because the annular volume is small, but the dose contribu-
tion from each particle is very high. At distances very far
away from the cell, the annular volume is much larger and
contains many more particles which each contribute a
much smaller dose to that cell. We separately compared
the dose contributions from 177Lu, 33P, and 90Y at different
distances from that cell in Fig. 6a, b, and c, respectively.
The vertical bars represent the percent of the total dose
contributed by each annulus, while the red curve across the
graph represents the cumulative dose from all annuli as r
increases. In Fig. 6d, e, and f, the x- and y-axes were
normalized to directly compare the three nuclides. The
Fig. 2 Dose Kernel Distribution; data recorded every 0.01 mm: a) Volume of each annulus with inner diameter on x-axis; b) Number of nuclei per
annulus as calculated in Methods section; c) Total absorbed dose per annulus in J/Bq-h; d) Absorbed dose per nucleus in J/Bq-h
Fig. 3 Dose Map: a) Map of total dose in Gy from 177Lu in all sections onto cells in section 171; b) Image of cell nuclei stained with DAPI; c)
Overlay of dose map onto the cell nucleus image. The black areas in b and c are areas of low cell density that therefore have no DAPI stain
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Fig. 4 Correlating Dose Map with Cytotoxicity: a) 177Lu Dose Map; b) Distribution of p-H2AX positive cells; Blue=DAPI; Red= p-H2AX immunostain; c)
Histogram showing the number of cells that received a given dose of radiation according to the dose map; d) Number of p-H2AX positive cells that
received a given dose; e) Percent of p-H2AX positive cells that received a given dose, taken from bins with > 1000 total cells as seen in c. As cells received
a higher dose of radiation, a higher percent of those cells stained positive for DNA double-stranded break repair, beginning around 1 Gy over 24 h
Fig. 5 Dose Map for 177Lu, 33P, and 90Y given identical source distribution: a-c) Dose maps and individual scale bars (in Gy) for 177Lu, 33P, and 90Y,
respectively; d-f) Cell distribution overlay for dose maps in a-c; g-i) Dose maps for 177Lu, 33P, and 90Y using the same scale bar min and max
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resulting histograms show that although the individual
particles closest to the cells each provide a large dose, the
cumulative dose from many particles in a slightly larger
(and further away) annulus contribute the most to the cell’s
dose. This is true for all three nuclides tested. We also see
that nearly 100% of the dose to a cell from 177Lu, 33P, and
90Y is provided by particles within radii of 1 mm, 0.3 mm,
and 5 mm, respectively.
Discussion
Herein, we have shown a novel method for calculating
tumor microdosimetry by measuring the actual hetero-
geneous distribution of nanoparticles carrying the radio-
nuclide 177Lu. We have done this by manually slicing
hundreds of adjacent tumor sections and generating a
3D stack of the nanoparticle distribution within the
tumor. This model has been validated in several different
ways: the radioactivity (in Bq) summed over each imaged
section agrees with total activity in the whole tumor im-
mediately after resection, the average absorbed dose in
Gy according to the model is similar to the average
absorbed dose according to both MIRD and single point
source dose kernel calculations, and the percentage of p-
H2AX-positive cells increases with increasing dose. The
dose found to initiate radiation-induced H2AX phos-
phorylation was approximately one Gy, which is similar
to doses in published articles which correlate H2AX
phosphorylation to 177Lu [31] and x-ray [32] treatment
across several cell types in vitro. Because externally
delivered x-ray doses are given over a short time to
induce acute damage, in contrast to β-emitters such as
177Lu which provide their dose continuously, x-ray-
mediated H2AX phosphorylation is induced at lower
doses and normalizes more rapidly [33, 34].
The largest preclinical advantage of this method may be
at the interface of tumor dosimetry and tumor biology. The
resolution of fluorescent microscopy is orders of magnitude
higher than techniques such as SPECT and PET, and fluor-
escence imaging has long been used to learn about tumor
biology as well as drug delivery. The high resolution of
these images allowed us to overlay our dose map onto
individual p-H2AX-positive cells to quantify dose response,
an approach that can be extended to quantify the dose to
specific areas such as blood vessels, tumor nests, or hypoxic
regions. These methods could be used to study how
different cell types and tumor conditions, such as hypoxia,
respond to radiation in vivo. Similarly, one could examine
how differences in the penetration of therapeutic nanofor-
mulations though vasculature or stroma affects the dose
rate to tumor cells, or how targeting ligands on nanoparti-
cles affect tumor dosimetry. In these cases, investigation is
only limited by image resolution and the accuracy of dose
kernels at short distances.
While our data suggests that this approach was success-
ful, there may be ways to recreate this experiment using a
less tedious and manually intensive approach. Light sheet
microscopy is a so-called volume imaging technique that
can image intact (and cleared [35]) organs as large as 1,000
mm3 by focusing the incident light in a thin sheet perpen-
dicular to the objective lens, and then moving the light
sheet in the z direction to excite fluorophores in each adja-
cent plane. The entire tissue can be imaged and stitched to-
gether in this manner, generating a 3D reconstruction of
the tissue without having to cut the tissue into sections.
Not only does this method reduce the manual labor associ-
ated with cutting and mounting hundreds of adjacent tissue
sections, but it also avoids the potential artifacts generated
from the stretching or folding of tissue sections as they are
Fig. 6 Dose Contributions for 177Lu, 33P, and 90Y at Different Distances from a Given Cell: a-c) Contributions to a cell’s total absorbed dose from
177Lu, 33P, and 90Y, respectively; d-f) Contributions with normalized x- and y-axes
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cut. The biggest downside to light sheet microscopy—and
volume imaging in general—is actually the issue of data
storage. One 1,000 mm3 3D image captured with high-
resolution light sheet technology can require over 30
terabytes of data per color channel [35], which not only ne-
cessitates a huge amount of storage capacity, but also
robust computing power when running the designated
algorithm. In contrast, the 342 downsampled (10 μm3
voxel) images that were used in this current research were
less than 100 Megabytes combined.
Conclusions
The work presented here represents a departure from
standard methods of calculating dosimetry, but the data
show that this method does indeed accurately model the
heterogeneous intratumoral distribution of nanoparticles
with very high resolution while also showing a positive cor-
relation with experimentally determined double-stranded
break repair. While it is easy to qualitatively observe the
distribution of fluorescent nanoparticles in a tumor, the
ability of this model to quantify the absorbed dose and dose
response in different intratumoral regions allows one to
investigate how source deposition in different tumor areas
can affect dose and cytotoxicity, as well as how characteris-
tics of the tumor microenvironment, such as hypoxia or
high stromal areas, may affect the potency of a given dose.
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